Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

PhRMA

Poll Respondents Appreciate Innovation’s Economic, Social Benefits And Call For More Protections

Washington, DC, November 30, 2017Mark Grayson, deputy vice president of public affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA), posts on the association’s blog, The Catalyst, that, increasingly, economists and international organizations are recognizing innovation as one of the most important drivers of economic and social progress and stability.

In fact, a report released earlier this year from the Global Intellectual Property Center, declared a robust innovation environment as “essential to the success of any 21st century economy.”

However, Grayson says it’s not just think tanks and academics acknowledging the value of innovation — the public is as well. Continue reading

PhRMA ‘Pipeline’ Report: 74 Percent of Medicines in Development Have Potential to Be First-in-Class Treatments

Washington, DC, November 11, 2017 — Seventy-four percent of medicines in clinical development around the world are potentially first-in-class medicines, meaning they use a completely new approach to fighting a disease, according to a September report by The Analysis Group, Inc. commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA).

“The Biopharmaceutical Pipeline: Innovative Therapies in Clinical Development” report examines the global state of the drug development pipeline and provides insights into new approaches biopharmaceutical researchers are pursuing.

The pipeline report, which updates a previous analysis, highlights new treatment approaches such as cell therapy and gene therapy, as well as DNA or RNA therapeutics and conjugated monoclonal antibodies. Continue reading

PhRMA Offers Consumers Online Resources on Biologics and Biosimilars

Washington, DC, November 10, 2017 ― Biological medicines often represent the cutting-edge of biomedical research and have revolutionized the treatment of a variety of medical illnesses and conditions that presently have no other treatments available.

A biosimilar product is exactly what its name implies — it is a biologic that is “similar” to another biologic drug already approved by the FDA.

To help increase awareness and understanding of the important scientific, regulatory and reimbursement policies for these medicines, the Pharmaceutical Research and Manufacturers of America (PhRMA) in March 2016 launched a new section of our website today that provides educational resources on these topics. Continue reading

PhRMA’s Chief Medical Officer on ‘The Next Five Years of PDUFA VI: Driving the Availability of Innovative Treatments for Patients’

Dr. Bill Chin

Washington, DC, October 13, 2017William “Bill” Chin, M.D., who serves as the chief medical officer of Pharmaceutical Research and Manufacturers of America (PhRMA) and leads the Scientific & Regulatory Advocacy department as executive vice president, wrote the following on PhRMA’s blog, The Catalyst, on October 2:

Yesterday, October 1, marked the first day of implementation for PDUFA VI, the next iteration of the Prescription Drug User Fee Act (PDUFA) and one of the best tools that the U.S. Food and Drug Administration (FDA) has for enhancing regulatory efficiency and encouraging innovative development of safe and effective new medicines for patients.

First enacted in 1992, PDUFA allows the FDA to collect user fees from biopharmaceutical companies to help support the agency’s process for review of new drugs and biologics. Continue reading

PhRMA Announces 2017 Research & Hope Award Honorees; Releases ‘Medicines in Development for Mental Illnesses Report’

Washington, DC, October 11, 2017 — As part of Mental Health Awareness Week, Pharmaceutical Research and Manufacturers of America (PhRMA) yesterday announced it is recognizing and honoring five individuals who are working tirelessly to advocate for patients, fight stigma surrounding mental illnesses and advance research at our 2017 Research & Hope Awards.

In addition, PhRMA said that America’s biopharmaceutical companies are committed to alleviating the considerable burden of mental illness and bringing cutting-edge medicines and new treatments to patients.

According to a new report — “Medicines in Development for Mental Illnesses 2017 Report” — released on October 10, there are more than 140 medicines in development to treat mental illnesses such as anxiety, depression, schizophrenia and more. Continue reading

PhRMA Announces Support for Seven-Day Script Limit on Opioid Medicines for Acute Pain

Washington, DC, October 3, 2017Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Stephen J. Ubl on September 27 issued the following statement regarding patient access to opioid medications:

“As part of our commitment to advancing a multifaceted solution to address the opioid crisis, today PhRMA is announcing it supports policies limiting the supply of opioids to seven days for acute pain treatment.

“We are taking this step because we believe the worsening opioid epidemic demands additional solutions, with new protections for patients. Continue reading

PhRMA’s New ‘Let’s Talk About Cost’ Campaign Convenes National Dialogue on Medicine Costs

Washington, DC, September 23, 2017Robert Zirkelbach, Executive Vice President of Public Affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA), in July posted on the association’s blog, The Catalyst:

Discussions about costs are important. We recognize that many are struggling to access the medicine they need and have important questions about their medicine costs.  And we want to help find the answers.

We recognize that many are struggling to access the medicine they need and have important questions about their medicine costs. And we want to help find the answers. Continue reading

Gov. Christie, Pharma Executives and Federal Leaders Discuss Public-Private Partnership to Address Opioid Epidemic

Governor Chris Christie

Trenton, NJ, September 19, 2017 — Governor Chris Christie, chairman of the President’s Commission on Combating Drug Addiction and the Opioid Crisis, yesterday joined Kellyanne Conway, Counselor to the President, and Former U.S. Rep. Patrick Kennedy, a commission member, in a roundtable at the War Memorial with leaders of the pharmaceutical industry, the National Institutes of Health (NIH) and the U.S. Food and Drug Administration (FDA) to advance a public-private partnership that can address America’s epidemic of addiction.

Governor Christie said, “The public and private sectors must join together to address this public health crisis and act quickly to stop an epidemic delivering a death toll equivalent to America enduring another 9-11 attack every two and a half weeks.” Continue reading

PhRMA Releases ‘Research in Your Backyard’ for New Jersey; PhRMA, HINJ and WWFH-NJ Host Discussion Focused on Biopharma Research in Garden State

New Brunswick, NJ, September 16, 2017 — The Pharmaceutical Research and Manufacturers of America (PhRMA) on June 28 released a new report entitled “Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in New Jersey,” which finds that 25,127 patients participated in clinical trials around the state in 2013, generating an estimated economic impact of $617 million.

The report was released at an event co-hosted by PhRMA, the HealthCare Institute of New Jersey (HINJ) and We Work for Health New Jersey (WWFH-NJ) that was held at the Rutgers Cancer Institute of New Jersey on June 28.

In addition to a presentation of the new PhRMA report, the event featured a panel discussion of industry experts that was moderated by HINJ President and Chief Executive Officer Dean J. Paranicas.  The panelists were: Continue reading

PhRMA’s ‘Research in Your Backyard’ for New Jersey Explores Clinical Trials’ State Impact

New Brunswick, NJ, September 15, 2017 — The Pharmaceutical Research and Manufacturers of America (PhRMA) on June 28 released a new report entitled “Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in New Jersey,” which finds that 25,127 patients participated in clinical trials around the state in 2013, generating an economic impact of $617 million.

The report was released at an event co-hosted by PhRMA, the HealthCare Institute of New Jersey (HINJ) and We Work for Health New Jersey (WWFH-NJ) that was held at the Rutgers Cancer Institute of New Jersey. Continue reading